Twitter Beğeni Hilesi

📢 Abstract submission for the ASCO 2025 Gastrointestinal Cancers Symposium is open! 🗓️ Deadline: September 24, 2024 View detailed information below on submitting an abstract including submission categories, guidelines, and policies👇 ow.ly/NAVB50SOSz6 #MedEd #ASCOGI25

❗Have you registered for the ILCA webinar on pediatric liver cancer? 🗓️ 10th September 2024 ⏰ 3PM CEST 💡 With speakers Prof. Dolores López-Terrada, Prof. Eiso Hiyama & Dr. Rebecka Meyers. Find out more information👇 ow.ly/4fMy50SOoWk #MedEd #HCC #LiverCancer

🚨 The deadline to register for #ESMO24 at discounted rates is at 23:59 CEST today! It is also the deadline to submit late breaking abstracts. Find out more information, including the complete programme👇 ow.ly/sb5z50SSLZF #MedEd #HCC ESMO - Eur. Oncology

💡Surveillance & diagnostic tools should be improved to identify HCC at an early stage What % of cases are diagnosed at an early stage due to surveillance strategies? Find out in our paper on improving outcomes of #HCC management in Asia👇 ow.ly/Pypl50SSsox #MedEd

✅ The decision for 2nd line therapy for #HCC is an assessment of toxicity, liver function and disease progression What data is needed to determine optimal 2nd line therapy? Listen here👇 ow.ly/jC1x50SSUrN Endorsed by Digestive Cancers Europe, Blue Faery & Global Liver Institute #MedEd

💡 4 year OS update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable #HCC Updated analysis showed sustained OS benefit with Single Tremelimumab Regular Interval Durvalumab vs sorafenib Read here👇 ow.ly/gX9650SSVC3 #MedEd Annals of Oncology

❗HCPs should monitor treatment side effects, maintain communication & enhance patient education What % of patients would have liked better communication to help them understand the disease? Find out in our paper on #HCC management in Asia👇 ow.ly/N9lI50SSX4o #MedEd

❓Have you read the most recent Global Liver Institute #LiverCancer News article? ➡️ Accelerated Refile for PD-1 Liver Cancer Combo After Surprise FDA Rejection ➡️ New Clinical Tool Can Help Identify Patients at High Risk for Liver Cancer Read here👇 ow.ly/OjwI50SSYxJ #MedEd #HCC

✅ In cases of slow progression, continuing IO based treatment should be considered for #HCC patients Do you know what are the treatment options after progression on #IO based treatment? Watch the interactive case video by Timon Vandamme to find out👇 ow.ly/yNJ650STgRO #MedEd

⚠️ New ASCO guidelines on systemic therapy for advanced #HCC 🟠 Following first-line treatment with atezo + bev; a TKI, ramucirumab, durva + treme, or nivo + ipi may be used 🟠 Following durva + treme, a TKI is recommended Full guidelines👇 ow.ly/2aBg50STlZg #MedEd

💡There is a need to improve patient access & affordability to HCC treatment options known to extend survival rates. Do you know the preferred first line treatment for advanced HCC? Find out in our paper on #HCC management in Asia👇 ow.ly/mSTF50STmZi #MedEd #LiverTwitter

📢 Registration is open for the EASLnews #LiverCancerSummit 2025! 🗓️ 20-22 February 📍 Paris, France Abstract submission deadline - 12 November Essential for staying at the forefront of liver cancer research and treatment. Find out more👇 ow.ly/r8PF50STr0j #MedEd

❗There is a cohort of patients with advanced #HCC who are not eligible for IO as a 1st line treatment option. Do you know what patients are part of this cohort? Find out in the interactive case presented by Prof. Sammy Saab👇 ow.ly/ltsW50STrJf #MedEd #LiverTwitter

🎉 ESMO Congress 2024 is nearly upon us! We've put together some abstracts we're looking forward to, look them up below: ow.ly/4BQK50TlRFI Follow HCC CONNECT for more updates, and check out our medical education👇 ow.ly/YFlx50TlRFH #MedEd #ESMO24 ESMO - Eur. Oncology

🚨 More abstracts from the ESMO - Eur. Oncology Congress 2024 Look them up from the complete list: ow.ly/5VQa50TlNuO 🗓️ 13-17 September 2024 📍Barcelona, Spain Follow HCC CONNECT for more updates and our independent medical education👇 ow.ly/Y24I50TlNuP #MedEd #ESMO24 #HCC

Updated data for atezo + bev vs surveillance in resected or ablated high risk HCC #ESMO24 🔎IMbrave050 👉RFS 33.2 vs 36 mo, HR 0.9 👉OS: HR: 1.26 🧐Benefit not sustained! Disappointing.. 🧐Caveat of (too) early read outs… ESMO - Eur. Oncology #ESMOAmbassadors @ILCA EASL Education

New data for #intermediate #HCC at #ESMO24 from LEAP-012 trial 👍🏻PFS/ORR benefit for LenvaPembro+TACE (vs TACE) 🤞🏻OS promising 🤝Toxicity acceptable 👉Systemic+TACE as SOC may be close to be a reality!! (2nd +ve study 😉 EMERALD-1) ESMO - Eur. Oncology #ESMOAmbassadors Grupo Español de Tratamiento de Tumores Digestivos EASLnews

Update from ESMO on IO and IO based treatments in HCC coming soon!

MO in #HCC at #ESMO24 (2/2) 5-year OS data from HIMALAYA with DurvaTreme 19.6% vs 9.4% OS rate at 5-years! Larger differences if disease control or response was achieved #Long-term #survivors are a reality in #HCC 😊 ESMO - Eur. Oncology #ESMOAmbassadors Grupo Español de Tratamiento de Tumores Digestivos EASLnews